



Nicole Burchardi

Kontakt

Nicole Burchardi

Publikationen (5)

Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). *Eur J Cancer* 2021; 156:138-148.

Kümmel S, Burchardi N, von Minckwitz G, Fasching P, Klare P, Engels K, Denkert C, Schneeweiss A, Jackisch C, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Blohmer J, Untch M, Schem C, Huober J, Paepke S, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). *Eur J Cancer* 2017; 84:1-8.

von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). *Cancer* 2015; 121:3639-48.

Hanusch C, Burchardi N, Engels K, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hilfrich J, Huober J, Jackisch C, Kümmel S, Paepke S, Untch M, Loibl S, Schneeweiss A, von Minckwitz G. Dual Blockade with Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). *Clin Cancer Res* 2015; 21:2924-31.

Pfisterer J, Arnold N, Burchardi N, Schmalfeldt B, Huober J, Harter P, Kommos F, Bentz E, du Bois A, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2009; 19:109-15.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch